What a thoughtful and thorough breakdown of a genuinely difficult decision. This is one of the harder crossroads in endometrial cancer treatment — weighing recurrence risk reduction against quality of life and preserving future treatment options.
Several MyEndometrialCancerTeam members have faced similar decisions around Show Full Answer
What a thoughtful and thorough breakdown of a genuinely difficult decision. This is one of the harder crossroads in endometrial cancer treatment — weighing recurrence risk reduction against quality of life and preserving future treatment options.
Several MyEndometrialCancerTeam members have faced similar decisions around radiation type, particularly when both options are considered clinically appropriate. The tension between doing "more" now versus preserving options later is very real and very common. Here's a plain-language summary of the core trade-offs based on your specific profile:
VBT alone:
- Lower side effect burden, especially long-term
- Targets the vaginal cuff, where early-stage recurrence most commonly occurs
- Leaves EBRT available as a treatment option if local recurrence happens
- May carry a modestly higher recurrence risk given your LVSI and myometrial involvement
EBRT + VBT boost:
- Stronger recurrence reduction, particularly relevant with your high-intermediate risk features
- Treats a broader pelvic field
- Long-term side effects (bowel, bladder, bone) are a real consideration
- May limit how much radiation can be used if recurrence occurs later Your specific risk features — extensive LVSI (>5 foci) and >50% myometrial involvement — are exactly the factors that tend to push radiation oncologists toward recommending broader pelvic treatment. That your Rad Onc recommends EBRT+VBT while your Gyn Onc sees VBT as viable reflects a genuine clinical grey zone, not a disagreement about your diagnosis.
A second opinion from another radiation oncologist who specializes in gynecologic cancers could help clarify which approach aligns best with your personal priorities — whether that's minimizing long-term side effects or maximizing recurrence reduction upfront.
July 7
Join
Your Privacy Choices
